Learn About Cone-Rod Dystrophy

What is the definition of Cone-Rod Dystrophy?

Cone-rod dystrophy is a group of related eye disorders that causes vision loss, which becomes more severe over time. These disorders affect the retina, which is the layer of light-sensitive tissue at the back of the eye. In people with cone-rod dystrophy, vision loss occurs as the light-sensing cells of the retina gradually deteriorate.

What are the causes of Cone-Rod Dystrophy?

Mutations in more than 30 genes are known to cause cone-rod dystrophy. Approximately 20 of these genes are associated with the form of cone-rod dystrophy that is inherited in an autosomal recessive pattern. Mutations in the ABCA4 gene are the most common cause of autosomal recessive cone-rod dystrophy, accounting for 30 to 60 percent of cases. At least 10 genes have been associated with cone-rod dystrophy that is inherited in an autosomal dominant pattern. Mutations in the GUCY2D and CRX genes account for about half of these cases. Changes in at least two genes cause the X-linked form of the disorder, which is rare.

How prevalent is Cone-Rod Dystrophy?

Cone-rod dystrophy is estimated to affect 1 in 30,000 to 40,000 individuals.

Is Cone-Rod Dystrophy an inherited disorder?

Cone-rod dystrophy is usually inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

Who are the top Cone-Rod Dystrophy Local Doctors?
Elite in Cone-Rod Dystrophy
Elite in Cone-Rod Dystrophy

University Of Pittsburgh Physicians

203 Lothrop St, 7th Floor, 
Pittsburgh, PA 
Languages Spoken:
English
Accepting New Patients

Jose-alain Sahel is an Ophthalmologist in Pittsburgh, Pennsylvania. Dr. Sahel is rated as an Elite provider by MediFind in the treatment of Cone-Rod Dystrophy. His top areas of expertise are Retinopathy Pigmentary Mental Retardation, Cone-Rod Dystrophy, X-Linked Congenital Stationary Night Blindness, Retinitis Pigmentosa, and Vitrectomy. Dr. Sahel is currently accepting new patients.

Elite in Cone-Rod Dystrophy
Ophthalmology
Elite in Cone-Rod Dystrophy
Ophthalmology

Scheie Eye Institute Perelman

3400 Civic Center Boulevard, West Pavilion, 3rd Floor, 
Philadelphia, PA 
Languages Spoken:
English
Accepting New Patients

Tomas Aleman is an Ophthalmologist in Philadelphia, Pennsylvania. Dr. Aleman is rated as an Elite provider by MediFind in the treatment of Cone-Rod Dystrophy. His top areas of expertise are Choroideremia, Leber Congenital Amaurosis, Retinopathy Pigmentary Mental Retardation, and Late-Onset Retinal Degeneration. Dr. Aleman is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Cone-Rod Dystrophy
Elite in Cone-Rod Dystrophy
Paris, FR 

Christina Zeitz practices in Paris, France. Ms. Zeitz is rated as an Elite expert by MediFind in the treatment of Cone-Rod Dystrophy. Her top areas of expertise are X-Linked Congenital Stationary Night Blindness, Cone-Rod Dystrophy, Retinopathy Pigmentary Mental Retardation, Late-Onset Retinal Degeneration, and Vitrectomy.

What are the latest Cone-Rod Dystrophy Clinical Trials?
A Phase 1/2a Study of Subretinal Administration of OpCT-001 Photoreceptor Precursor Cells Derived From iPSCs in Patients With Primary Photoreceptor Disease

Summary: Study OpCT-001-101 is a Phase 1/2a first-in-human, multisite, 2-part interventional study to evaluate the safety, tolerability, and the effect on clinical outcomes of OpCT-001 in up to approximately 54 adults with primary photoreceptor (PR) disease. Phase 1 will focus on safety and features a dose-escalation design. Phase 2 is designed to gather additional safety data and assess the effect of OpCT...

Match to trials
Find the right clinical trials for you in under a minute
Get started
ACDN-01-001: Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Subretinal ACDN-01 in Participants With ABCA4-related Retinopathy

Summary: This study is an open-label, single ascending dose clinical trial in participants who have ABCA4-related retinopathies. This is the first-in-human clinical trial in which ACDN-01 will be evaluated for safety, tolerability, and preliminary efficacy following a single subretinal injection of ACDN-01.

Who are the sources who wrote this article ?

Published Date: March 01, 2018
Published By: National Institutes of Health